The latest price target for Kaleido Biosciences (OTCEM:KLDO) was reported by Chardan Capital on April 4, 2022. The analyst firm set a price target for $1.70 expecting KLDO to rise to within 12 months (a possible 169999900.00% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Kaleido Biosciences (OTCEM:KLDO) was provided by Chardan Capital, and Kaleido Biosciences downgraded their neutral rating.

There is no last upgrade for Kaleido Biosciences

The last downgrade for Kaleido Biosciences Inc happened on April 4, 2022 when Chardan Capital changed their price target from $3 to $1.7 for Kaleido Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kaleido Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kaleido Biosciences was filed on April 4, 2022 so you should expect the next rating to be made available sometime around April 4, 2023.

While ratings are subjective and will change, the latest Kaleido Biosciences (KLDO) rating was a downgraded with a price target of $3.00 to $1.70. The current price Kaleido Biosciences (KLDO) is trading at is $0.00, which is out of the analyst’s predicted range.